A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 110
- 试验地点
- 5
- 主要终点
- Change in Serum AFP Levels
研究概览
简要总结
This randomized phase II trial studies how well S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) works compared to a placebo in preventing liver cancer in patients with chronic hepatitis C infection. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of SAMe may keep cancer from forming in patients with advanced liver disease
详细描述
PRIMARY OBJECTIVE:
I. To determine whether treatment with SAMe for 24 weeks reduces serum level of alpha-fetoprotein (AFP) in patients with advanced liver disease due to chronic hepatitis C.
SECONDARY OBJECTIVE:
I. To determine whether treatment with SAMe for 24 weeks reduces serum levels of des-gamma carboxyprothrombin (DCP) and alpha-fetoprotein-L3 (AFP-L3) in patients with advanced liver disease due to chronic hepatitis C (hepatocellular carcinoma tumor markers).
II. To determine whether treatment with SAMe for 24 weeks alters biochemical markers of liver disease (e.g., serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], albumin, or bilirubin, etc.) and hepatitis C viral load in patients with advanced liver disease due to chronic hepatitis C (hepatitis C liver disease).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic hepatitis C infection diagnosed by presence of hepatitis C ribonucleic acid (RNA) in serum by test of hepatitis C virus (HCV) RNA
- •No significant alcohol use (7 or fewer drinks per week) for the past 12 months
- •Serum AFP (at screening) between 15 and 100 ng/mL (15 ng/mL =< AFP =< 100 ng/mL) as measured by the Bayer Advai Centaur chemiluminescence system OR Serum AFP between 10 and 100 ng/mL (10 ng/mL =< AFP =<100 ng/mL) as measured by Diagnostic Products Corporation Immulite assay system OR AFP between 12 and 100 ng/mL (12 ng/mL =< AFP =< 100 ng/mL) as measured by Ortho ECiQ assay system
- •Evidence of advanced liver disease based on one or more of the following:
- •Platelet count less than 150,000/mm^3
- •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio > 0.75
- •Liver biopsy demonstrating bridging fibrosis or cirrhosis
- •No treatment with interferon (recombinant interferon alfa), peginterferon (PEG-interferon alfa-2b), or ribavirin for at least 4 months, and not anticipated to start specific treatment for hepatitis C during the study (30 weeks)
- •Ultrasound (or adequate computed tomography [CT] or magnetic resonance imaging [MRI]) examination of the liver within 6 months prior to randomization revealing no masses in the liver suggestive of hepatocellular carcinoma
- •Willing to refrain from consuming over-the-counter SAMe and vitamin pills containing B-vitamins while participating in this study (30 weeks)
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •Leukocytes > 1,000/ mm^3
- •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- •Ability to understand and the willingness to sign a written informed consent document
排除标准
- •Liver disease other than from hepatitis C (e.g., hepatitis B, hemochromatosis, fat in more than 33% of hepatocytes, if liver biopsy has been performed., etc.); subjects with a past history of alcohol use can be enrolled into the study provided they have consumed less than 7 drinks/week for the past 12 months
- •Evidence of mass in liver by radiologic examination that is suggestive of hepatocellular carcinoma within 6 months prior to randomization
- •Model for End-Stage Liver Disease (MELD) score greater than 15 within 60 days prior to enrollment
- •Ascites which is clinically detectable
- •Use of SAMe during 4 months prior to randomization
- •Hospitalization within the past 5 years for mania or for bipolar disease
- •Concurrent use of monoamine oxidase inhibitors (MAO) or other drugs that increase the concentration of serotonin
- •Participants may not be receiving any other investigational agents
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAMe
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Children are excluded from this study but will be eligible for future pediatric trials, if applicable
- •Pregnant women are excluded from this study; serum pregnancy must be performed and be negative in all women of child bearing potential within 2 weeks prior to enrollment; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with SAMe, breastfeeding should be discontinued if the mother is treated with SAMe
- •Subjects with any medical psychosocial condition that, in the opinion of the investigator, could jeopardize the subject's participation in and compliance with the study criteria
研究组 & 干预措施
Arm I (SAMe)
Patients receive SAMe PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
干预措施: S-adenosyl-L-methionine disulfate p-toluene-sulfonate (Drug)
Arm I (SAMe)
Patients receive SAMe PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
Arm I (SAMe)
Patients receive SAMe PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
干预措施: immunoenzyme technique (Other)
Arm I (SAMe)
Patients receive SAMe PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
干预措施: high performance liquid chromatography (Other)
Arm II (placebo)
Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
干预措施: placebo (Other)
Arm II (placebo)
Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
Arm II (placebo)
Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
干预措施: immunoenzyme technique (Other)
Arm II (placebo)
Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
干预措施: high performance liquid chromatography (Other)
结局指标
主要结局
Change in Serum AFP Levels
时间窗: Baseline to week 24
Measured using an Food and Drug Administration (FDA)-approved assay. Mean change over time for the SAMe and placebo groups will be estimated. Differences in the change over time between the treated and control groups will be tested using a two-group repeated measures analysis of variance model.
次要结局
- SAMe(Baseline to week 24)
- Change in SAMe Metabolites - S-adenosylhomocysteine (SAH)(Baseline to week 24)
- Change in SAMe Metabolites - Methionine(Baseline to week 24)
- Change in SAMe Metabolites - Total Homocysteine (tHcy)(Baseline to week 24)
- Treatment-related Changes in Serum DCP for Hepatocellular Carcinoma(Baseline to week 24)
- Treatment-related Changes in Serum AFP-L3 (Expressed as the Percentage of Total AFTP) for Hepatocellular Carcinoma(Baseline to week 24)
- Change in SAMe Metabolites - Plasma GSH(Baseline to week 24)
- Change in SAMe Metabolites - Malondialdehyde (MDA)(Baseline to week 24)
- Change in SAMe Metabolites - 4-hydroxynonenal (4-HNE)(Baseline to week 24)
- Change in Markers of Liver Disease - AST(Baseline to week 24)
- Change in Markers of Liver Disease - ALT(Baseline to week 24)
- HCV RNA(Baseline to week 24)
- Changes in Quality of Life - Physical Score(Baseline to week 24)
- Changes in Quality of Life - Mental Score(Baseline to week 24)
研究者
Chao Family Comprehensive Cancer Center
Cancer Center
University of California, Irvine